Skip to main content
. 2021 May 14;43(3):672–680. doi: 10.1038/s41401-021-00683-8

Fig. 2. The anti-HER2×PD1 BsAb simultaneously bound to PD-1 and HER2.

Fig. 2

a The binding affinity of the BsAb for HER2 was measured by ELISA. Trastuzumab was used as the positive control. b The binding affinity of the BsAb for PD1 was measured by ELISA and compared to that of the parental anti-PD1 mAb, 609A. c The ability of the BsAb to bind to BT474, a HER2-overexpressing cancer cell line, was measured by FACS and compared to that of trastuzumab. d The ability of the BsAb to bind to PD1-overexpressing CHO cells was measured by FACS and compared to that of the parental anti-PD1 mAb, 609A. e A bridging ELISA was set up such that PD1 proteins were coated on the plates followed by the sequential addition of the indicated antibodies and His-tagged HER2 proteins. Anti-6×HisTag monoclonal antibody-HRP was added to visualize the positive binders. The results confirm that the BsAb is capable of simultaneously crosslinking its two targets, HER2 and PD1.